Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at treating rare metabolic diseases. Focusing on disorders linked to paradoxical mineralization, Inozyme is pioneering solutions for conditions impacting vasculature, soft tissue, and skeletal health. Their lead drug, INZ-701, is an enzyme replacement therapy designed to correct defects in pathways involving ENPP1 and ABCC6 deficiencies.
INZ-701 showcases promise in treating diseases such as pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI). This drug, currently in Phase 1/2 clinical trials, has demonstrated positive preliminary results, including safety, pharmacokinetic, and pharmacodynamic data, as well as trends toward clinical improvement. The trials indicate that INZ-701 increases plasma pyrophosphate (PPi) levels, a crucial marker for these conditions.
During the trials, INZ-701 was generally well tolerated with favorable safety profiles. Inozyme has undertaken comprehensive natural history studies to better understand the progression of ABCC6 Deficiency, especially in pediatric populations at high risk for severe complications like strokes.
In addition to their clinical advancements, Inozyme is committed to expanding its pipeline and therapeutic focus, planning pivotal trials for both pediatric and adult populations affected by these genetic disorders. The company also actively engages with patient communities and global health institutions to further research and raise awareness.
For real-time updates and detailed information, visit Inozyme Pharma or follow them on LinkedIn, X (formerly Twitter), and Facebook.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases, announced that Douglas A. Treco, Ph.D., CEO and Chairman, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, from 9:30 to 10:10 AM ET.
A live webcast of this event will be available on the Investor Relations section of Inozyme's website, along with a replay for a limited time.
Inozyme is developing INZ-701, an enzyme replacement therapy targeting pathologic mineralization and intimal proliferation associated with severe diseases. Currently, INZ-701 is in Phase 1/2 clinical trials for ENPP1 Deficiency and ABCC6 Deficiency.
Inozyme Pharma (Nasdaq: INZY) announced the grant of an inducement award to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D., effective April 3, 2023. The award includes a nonstatutory option to purchase up to 250,000 shares at an exercise price of $5.39 per share, corresponding to the company's closing share price on the grant date. The option has a 10-year term and vests over four years. Inozyme Pharma specializes in developing therapeutics for rare diseases, including therapies like INZ-701 for pathologic mineralization, currently in Phase 1/2 clinical trials.
Inozyme Pharma (Nasdaq: INZY) announced the retirement of founding CEO Axel Bolte, effective April 1, 2023, with Douglas A. Treco, Ph.D. set to succeed him. Matthew Winton, Ph.D. has been appointed COO. Recent financial results for the year ending December 31, 2022, show a net loss of $67.1 million, or $1.78 per share. However, the company maintains a strong cash position of $127.9 million and expects to fund operations into Q4 2024. Ongoing clinical trials for INZ-701 show positive topline data, and the company is on track for pivotal trial initiation later this year.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases, announced that CEO Axel Bolte will be part of the Neuromuscular and Bone Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, from 2:10-3:10 pm ET in Boston. The event will highlight the company’s innovative therapeutic initiatives aimed at treating pathologic mineralization and intimal proliferation. A replay of the panel will be available on their Investor Relations page for a limited time after the event. Inozyme is developing INZ-701, currently in Phase 1/2 trials for ENPP1 and ABCC6 Deficiencies.
Inozyme Pharma announced positive topline results from its Phase 1/2 trials of INZ-701 for ENPP1 and ABCC6 deficiencies. Results showed a significant increase in plasma pyrophosphate (PPi) across all dose cohorts, with normal levels sustained in the highest dosage. Patient-reported outcomes indicated improvements in health for the majority of participants. INZ-701 was well-tolerated, showing a favorable safety profile with no serious adverse events. The company expects its cash reserves to fund operations into the fourth quarter of 2024, enhancing its clinical development pathway.
Inozyme Pharma (Nasdaq: INZY) will host an Investor and Analyst Event on February 16, 2023, at 8 a.m. ET to discuss topline data from its ongoing Phase 1/2 trials of INZ-701 targeting ENPP1 and ABCC6 Deficiency. The event will feature key opinion leaders, including Michael Levine, Wilko Spiering, and Mark Kiel, who will discuss the therapeutic implications and development milestones of INZ-701. This clinical trial aims to demonstrate the safety, tolerability, and pharmacokinetics of INZ-701 in patients affected by these rare conditions, for which there are currently no approved therapies.
Inozyme Pharma (Nasdaq: INZY) will present topline data from its ongoing Phase 1/2 trials of INZ-701 for ENPP1 and ABCC6 Deficiencies during a virtual event on February 16, 2023. In 2022, the company reported significant advancements in both programs, including evidence of INZ-701's impact on pyrophosphate (PPi) levels, crucial for mineralization regulation. The trials are aimed at evaluating safety, pharmacokinetics, and pharmacodynamics of INZ-701, with previous positive results noted in both trials. The event will feature presentations from Inozyme's management and key opinion leaders.
Inozyme Pharma (Nasdaq: INZY) announced a groundbreaking study revealing the genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies—more than tripling previous estimates. The research estimates a global patient population of 37,000, including 2,800 in North America, 4,100 in Europe, and 900 in Japan. The study highlights an urgent need for therapies as many affected individuals remain undiagnosed. The company is developing INZ-701, an enzyme therapy currently in Phase 1/2 trials for ENPP1 and ABCC6 Deficiencies.
Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, has announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on December 8, 2022, from 8:00-8:30am ET. The event will showcase insights into the company’s work on novel therapeutics, particularly INZ701, a potential first-in-class enzyme therapy for pathologic mineralization and intimal proliferation.
A replay will be available on their website after the event.
Inozyme Pharma reported financial results for Q3 2022, highlighting ongoing Phase 1/2 trials of INZ-701 for ENPP1 and ABCC6 deficiencies. Dosing is underway in the third cohort for both trials, with topline data expected in Q4 2022 and Q1 2023, respectively. The cash position stood at $141.5 million, sufficient to fund operations into Q2 2024. R&D expenses increased to $12.2 million due to trial progress, while G&A expenses slightly decreased. The net loss was $16.4 million, or $0.38 per share, compared to $14.3 million, or $0.60 per share, a year ago.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
What does Inozyme Pharma specialize in?
What is INZ-701?
What conditions is INZ-701 intended to treat?
What are the latest clinical trial results for INZ-701?
What are ENPP1 and ABCC6 Deficiencies?
Does Inozyme Pharma have any ongoing clinical trials?
What is the significance of plasma pyrophosphate (PPi) levels?
What partnerships does Inozyme Pharma have?
How can I stay updated on Inozyme Pharma's progress?
What are Inozyme Pharma's future plans?
